| Literature DB >> 20223524 |
Yu-Ming Shiao1, Chin-Cheng Lee, Yung-Hsiang Hsu, Shiu-Feng Huang, Chung-Yen Lin, Ling-Hui Li, Cathy S-J Fann, Chang-Youh Tsai, Shih-Feng Tsai, Hou-Chang Chiu.
Abstract
Myasthenia gravis (MG) is an antibody and complement mediated autoimmune disease. Serum CXC chemokine ligand 13 (CXCL13) was found to be elevated in MG patients and high CXCL13 level was associated with severe clinical stages, especially in females with thymic lymphoid hyperplasia. Both protein and mRNA of CXCL13 and CXC chemokine receptor 5 (CXCR5) in the thymic tissues were significantly higher in MG patients with lymphoid hyperplasia than those with thymoma. Our data indicated that serum CXCL13 can be used as an index of disease severity and ectopic thymic expression of CXCL13 might be associated with aberrant cell trafficking to the thymus of MG. Copyright 2010 Elsevier B.V. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20223524 DOI： 10.1016/j.jneuroim.2010.02.013
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478